mva.hivconsv
Vaccineexperimental
Clinical trial activity
10 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01024842)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva.hivconsv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054931 | Phase 2 | Sep 5, 2025 | University of Oxford |
| NCT06484335 | Phase 1 | Feb 1, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT06071767 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2024 | Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, University of Pittsburgh |
| NCT04586673 | Phase 1 | Nov 1, 2020 | University of Oxford |
| NCT03844386 | Phase 1 | Apr 22, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT02616874 | Phase 1 | Feb 1, 2016 | Badalona Hospital Germans Trias i Pujol, BCN-Checkpoint, Fundacio Lluita Contra la SIDA, HIVACAT, Hospital de Sant Pau i Santa Tecla de Tarragona, IrsiCaixa, University of Barcelona, University of Oxford |
| NCT02336074 | Phase 2 | Nov 27, 2015 | Medical Research Council, University of Cambridge, University of London, University of Oxford, University of Sussex |
| NCT02425241 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | GlaxoSmithKline, Medical Research Council, University of London, University of Oxford |
| NCT01712425 | Phase 1 | Oct 1, 2012 | Fundacio Lluita Contra la SIDA, HIVACAT, Institut de Recerca de la Sida IrsiCaixa-HIVACAT, IrsiCaixa, University of Barcelona, University of Oxford |
| NCT01024842 | Phase 1 | Dec 1, 2009 | Medical Research Council, University of Oxford |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (20)
20 organizations
Page 1 / 1